Invention Grant
- Patent Title: Use of pteridinone derivative serving as EGFR inhibitor
-
Application No.: US15577518Application Date: 2016-05-30
-
Publication No.: US11306095B2Publication Date: 2022-04-19
- Inventor: Honglin Li , Yufang Xu , Zhenjiang Zhao , Wei Zhou , Yuqiong Xu , Deheng Sun , Xia Wang , Zhuo Chen
- Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
- Applicant Address: CN Shanghai
- Assignee: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
- Current Assignee: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
- Current Assignee Address: CN Shanghai
- Agency: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
- Priority: CN201510289399.4 20150529
- International Application: PCT/CN2016/083945 WO 20160530
- International Announcement: WO2016/192609 WO 20161208
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61P35/00 ; A61P35/02 ; A61K31/519 ; C07D475/00
Abstract:
The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.
Public/Granted literature
- US20180148454A1 USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR Public/Granted day:2018-05-31
Information query
